ClinicalTrials.gg
RecruitingNCT07638215Updated Oct 8, 2026

A Single-Center Clinical Study to Evaluate the Efficacy and Safety of Sutureless Ophthalmic Hydrogel for Corneal Wound Repair

An interventional study of Sutureless Ophthalmic Hydrogel for Corneal Stromal Defects in Corenal Diseases, sponsored by Suxia Li. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Suxia Li · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2025, registered Apr 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 8, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Corneal blindness is one of the leading causes of blindness worldwide. For various infectious and non-infectious corneal diseases, current clinical repair strategies include corneal lesion debridement, conjunctival flap coverage, amniotic membrane transplantation, corneal transplantation, contact lens application, and injectable sealants. Injectable hydrogels, as smart materials that transition from a liquid precursor to a solid gel in response to external stimuli (e.g., light, temperature, or chemical cross-linking), enable precise filling of corneal defects via minimally invasive injection. They offer superior morphological adaptability, conforming tightly to irregular wound surfaces and achieving sutureless closure. Moreover, they promote regenerative repair of the epithelium, stroma, and nerves, significantly reducing patient discomfort, infection risk, recovery time, and healthcare costs, thereby advancing the paradigm of corneal repair from "transplant substitution" to "in situ regeneration."

02

Conditions studied

  • Corenal Diseases
03

In context

Lead sponsor

Suxia Li is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You must meet all the following inclusion criteria to participate in the study:

    1. Patients with corneal stromal defects, including those caused by trauma or following lesion excision for infection, with a residual stromal thickness of ≥300 μm in the defect area.
    2. Patients aged 18 to 85 years (inclusive, either sex) at the time of consent.
    3. Patients who are capable of providing written voluntarily to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • You will be excluded from the study if you meet any of the following exclusion criteria:

    1. Patients with unexplained keratoconjunctival diseases.
    2. Patients with severe dry eye, symblepharon, corneal neovascularization, or other ocular surface disorders.
    3. Patients with systemic infectious diseases (positive for bacteria/fungi////TP, etc.).
    4. Patients with diseases such as rheumatoid arthritis, Sjögren's syndrome, or .
    5. Patients with uncontrolled ocular diseases in the study eye.
    6. Patients with major organ failure or other serious systemic conditions, including but not limited to cardiac insufficiency; poorly controlled diabetes mellitus (fasting blood glucose >8 mmol/L despite glucose-lowering therapy); uncontrolled stage II or higher hypertension (blood pressure >160/100 mmHg despite antihypertensive therapy); history of within the past 5 years; severe immunodeficiency, etc.
    7. Patients with psychiatric disorders that may interfere with treatment or evaluation.
    8. Pregnant or lactating women, or women planning to become pregnant during the clinical study.
    9. Patients deemed unsuitable for participation in the clinical trial by the investigator.
    10. Patients unable to complete follow-up visits.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Sutureless Ophthalmic Hydrogel for Repairing Corneal Stromal Defects

    Biological: Sutureless Ophthalmic Hydrogel for Corneal Stromal Defects

Interventions

  • BiologicalSutureless Ophthalmic Hydrogel for Corneal Stromal Defects

    Surgery was performed under peribulbar block anesthesia. After excision of the corneal lesion, the surface moisture of the recipient bed was dried with a sponge, and a cotton pad was placed over the pupillary area to protect the fundus. The hydrogel was pre-liquefied in a 37 °C water bath, then instilled into the lamellar defect using a sterile syringe, followed by irradiation with a 365 nm light source at an intensity of 18 mW/cm² for 30 seconds to achieve curing. A bandage contact lens could be applied.

06

What researchers measure

Primary outcomes

  1. Incidence of Ocular Adverse Events and Hydrogel-Related Ocular Complications (Irritation, Displacement, Infection, Corneal Cell/Epithelial Changes)

    Description: Assess ocular safety outcomes including: * Ocular surface irritation symptoms (eye redness, foreign body sensation, tearing, photophobia, etc.) * Hydrogel adhesion status (presence or absence of hydrogel displacement or detachment) * Corneal infection * Corneal endothelial cell morphology and density changes * Corneal epithelial healing time The incidence and severity of all events will be recorded.

    Time frame: 1st day, 1st week, 2nd week, 1st month and 2nd month postoperatively

Secondary outcomes

  1. Corneal Clarity Full Rating Scale (0-4 points full-scale assessment for corneal transparency after hydrogel repair)

    Observe the transparency of the cornea in the hydrogel transplantation area using a slit lamp examination, score it, and record the corneal transparency scores at different follow-up time points. Full scale information: Minimum score = 0, Maximum score = 4; higher scores indicate worse corneal opacity/poorer corneal clarity, lower scores indicate better corneal transparency. Scoring criteria: 0 = completely transparent; 1. = slight opacity, not easily detectable under direct illumination; 2. = mild opacity, visible under slit lamp; 3. = moderate opacity, partially obscuring the iris; 4. = severe opacity, obscuring details of intraocular structures.

    Time frame: 1st day, 1st week, 2nd week, 1st month and 2nd month postoperatively

  2. Change in corneal thickness (OCT measurement, µm)

    Use corneal OCT to observe changes in corneal thickness in the hydrogel transplantation area, and record the residual corneal thickness, hydrogel thickness, and total corneal thickness at different follow-up time points.

    Time frame: 1st day, 1st week, 2nd week, 1st month and 2nd month postoperatively

  3. Change in visual acuity (decimal chart)

    Use a decimal visual acuity chart to record the visual acuity and best corrected visual acuity at different follow-up time points, and evaluate the recovery and changes in visual acuity

    Time frame: 1st day preoperatively, 1st day, 1st week, 2nd week, 1st month and 2nd month postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start May 2026 → Sep 2025 and completion Jun 2027 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2026
First posted
Jun 10, 2026
StartActual
Sep 1, 2025was May 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027was Jun 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
1 site added — first site in China
Show site
  • Shandong Eye Hospital · Jinan, China
Oct 8, 2026
Start date
May 22, 2026→Sep 1, 2025 (actual)
Oct 8, 2026
Study completion
Jun 1, 2027→Jan 1, 2027
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Shandong Eye Hospital · Jinan, China
    Start date May 22, 2026→Sep 1, 2025 (now actual)
    Study completion Jun 1, 2027→Jan 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07638215
Lead sponsor
Suxia Li
Responsible party
Suxia Li (Prof., Shandong Eye Hospital) — Sponsor-investigator
First posted
Jun 10, 2026
Start date
Sep 1, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Suxia Li
Contact
lsuxiasusu@163.com
+86 158 5410 7085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion